Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
UK-based digital therapy company focused on mental disorders.
Big Health is a digital therapeutics company dedicated to helping millions back to good mental health. Its first digital therapeutics Sleepio, for poor sleep and Daylight, for worry and anxiety are fully automated, scalable cognitive and behavioural programs. Big Health’s products are backed by 50 published clinical papers including 13 randomised controlled trials (RCTs), and are cited in leading clinical guidelines including the American College of Physicians and NICE. Today, over 12 million people worldwide have reimbursed access to Big Health’s products, via leading employers in the US and the UK’s NHS.
More Big Health news
Gilde Healthcare company Big Health receives US FDA Clearance for DaylightRx
Gilde Healthcare company Big Health expands into adolescent mental health through acquisition of Limbix
Gilde Healthcare company Big Health builds out its Leadership Team with the appointment of five key Executives
Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness
Gilde Healthcare Portfolio Company Big Health Adds Former FDA Deputy Commissioner Anand Shah to Its Board of Directors
Gilde Healthcare Portfolio Company Big Health Raises $75 Million in Series C Funding
Gilde Healthcare leads $39 million in Series B financing in Big Health
Venture&Growth
Tagworks
Tagworks Pharmaceuticals is a privately held therapeutics company based in the Netherlands. It leverages unique technologies to increase efficacy and decrease toxicity across multiple systemic treatment modalities. The company has pioneered a unique and proprietary Click-to-Release drug development technology, enabling
Venture&Growth
Okami Medical
Okami Medical, based in Aliso Viejo, California and founded in 2017 by the Inari team through the Inceptus Medical incubator, is a commercial-stage company focused on innovative solutions for peripheral vascular embolization across a wide range of conditions. The company’s
Venture&Growth
Amphista Therapeutics
Amphista Therapeutics is a UK-based company creating first-class therapeutics to selectively degrade and remove disease-causing proteins by harnessing the body’s natural processes. It’s next generation targeted protein degradation TPD-based medicines leverage novel mechanisms that make use of a wider range